Thursday, December 31, 2009

Subcellular targeting strategies for drug design and delivery

Nature Reviews Drug Discovery 9, 29-42 (January 2010) | doi:10.1038/nrd2897

Lawrence Rajendran , Hans-Joachim Kn|[ouml]|lker & Kai Simons  

Keywords: drug targets, drug design strategies,  bioavailability,  tissue targeting, specific intracellular compartments.

Tuesday, December 29, 2009

Molecular diagnostics: techniques and applications for the clinical laboratory

Book review.

Wayne Grody, UCLA School of Medicine, Los Angeles, CA, USA Professor Divisions of Medical Genetics and Molecular Pathology Departments of Path. & Lab. Medicine, Pediatrics, and Human Genetics UCLA School of Medicine Los Angeles, CA 90095-1732
Robert Nakamura, Scripps Clinic, La Jolla, CA, U.S.A.
Frederick Kiechle, Medical Director, Clinical Pathology Department of Pathology Pathology Consultants of South Broward Memorial Healthcare System
Charles Strom, Medical Director, Genetic Testing Center Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA, U.S.A. s

Hardbound, 736 pages, publication date: DEC-2009
ISBN-13: 978-0-12-369428-7
ISBN-10: 0-12-369428-0
Imprint: ACADEMIC PRESS

In Vivo Fluorescent Detection of Fe-S Clusters Coordinated by Human GRX2

Kevin G. Hoff124,Stephanie J. Culler14Peter Q. Nguyen2Ryan M. McGuire3Jonathan J. Silberg23, and Christina D. Smolke1
1 Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E. California Boulevard, Mail Code 210-41, Pasadena, CA 91125, USA
2 Department of Biochemistry and Cell Biology, Rice University, 6100 Main Street, MS 140, Houston, TX 77005, USA
3 Department of Bioengineering, Rice University, 6100 Main Street, MS 140, Houston, TX 77005, USA

Keywords: Fe-S cluster biosynthesis, fluorescent approach, 2Fe2S clusters, Venus fluorescent protein, glutaredoxin 2 (GRX2), ISCU, NFS1. 

Splitting Fluorescent Protein Helps Image Clusters in Live Cells

AZoM.com Pty.Ltd


Posted December 24th, 2009


Keywords: Iron-sulfur clusters, Friedreich's ataxia, sideroblastic anemia, myopathy, fluorescent protein, GRX2, iron-sulfur irregularities, American Heart Association, Friedreich's Ataxia Research Alliance, Robert A. Welch Foundation.

Friday, December 25, 2009

A structural and functional homolog supports a general role for frataxin in cellular iron chemistry

Communication:

Chem. Commun.2010, DOI: 10.1039/b911975b

Wenbin Qi and J. A. Cowan

Keyword:  Bacillus subtilis,  YdhG, frataxin family, iron homeostasis.

Tuesday, December 22, 2009

Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

This study is currently recruiting participants.
Verified by Penwest Pharmaceuticals Co., December 2009
First Received: December 17, 2009   Last Updated: December 18, 2009   History of Changes
Sponsor:
Penwest Pharmaceuticals Co.
Information provided by:
Penwest Pharmaceuticals Co.
ClinicalTrials.gov Identifier:
NCT01035671



Condition Intervention Phase
Friedreich's Ataxia
Drug: alpha-tocopherolquinone (A0001)
Drug: placebo
Phase II

Sunday, December 20, 2009

Age and Dietary Iron Affect Expression of Genes Involved in Iron Acquisition and Homeostasis in Young Pigs.

J Nutr. 2009 Dec 16. [Epub ahead of print]

Department of Animal Science, North Carolina State University, Raleigh, NC 27695-7621.

Highlight:  "frataxin decreased with age of the animal", " the expression of some genes examined in this study was affected by age".

Saturday, December 19, 2009

Coenzyme q10 in neuromuscular and neurodegenerative disorders.

Current drug targets. 2010 Jan;11(1):111-21.

Department of Neuroscience, Neurological Clinic, University of Pisa, Italy, Via Roma 67, 56126 Pisa, Italy

Keywors:  Coenzyme Q10 (CoQ10, or ubiquinone), electron transport chain, oxidative phosphorylation, cellular antioxidant protection, energy metabolism, antioxidant status, neuromuscular and neurodegenerative disorders, idebenone,  mitochondrial disorders, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, clinical practice.

Wednesday, December 16, 2009

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study

Pieter Stolk , Harald E Heemstra , Hubert GM Leufkens , Brigitte Bloechl-Daum and Eibert R Heerdink

Orphanet Journal of Rare Diseases 2009, 4:27doi:10.1186/1750-1172-4-27
Published: 14 December 2009

OPEN ACCESS

Background

Regulators and payers have to strike a balance between the needs of the patient and the optimal allocation of resources. Drugs indicated for rare diseases (orphan medicines) are a special group in this context because of their often high per unit costs. Our objective in this pilot study was to determine, for drugs used in an outpatient setting, how utilisation of centrally authorised drugs varies between countries across a selection of EU member states.

Methods
We randomly selected five orphan medicines and nine other drugs that were centrally authorised in the European Union between January 2000 and November 2006. We compared utilisation of these drugs in six European Union member states: Austria, Denmark, Finland, Portugal, The Netherlands, and Sweden. Utilisation data were expressed as Defined Daily Doses per 1000 persons per year. Variability in use across countries was determined by calculating the relative standard deviation for the utilisation rates of individual drugs across countries.

Results
No association between orphan medicine status and variability in use across countries was found (P=0.52). Drugs with an orphan medicine status were more expensive and had a higher innovation score than drugs without an orphan medicine status.

Conclusions
The results show that the variability in use of orphan medicines in the different health care systems of the European Union appears to be comparable to the other newly authorised drugs that were included in the analysis. This means that, although strong heterogeneity in access may exist, this heterogeneity is not specific for drugs with an orphan status.

Full Text pdf

Tuesday, December 15, 2009

Epigenetics specialists plan to edit the 'book of life'

FierceBiotech Research Newsletter, December 15, 2009

Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program

Download and print (PDF)

Iron binding activity in yeast frataxin entails a trade off with stability in the α1/β1 acidic ridge region

Biochem. J. (2009) Immediate Publication, doi:10.1042/BJ20091612

Ana R. Correia, Tao Wang, Elizabeth A. Craig and Cláudio M. Gomes.
Instituto Tecnologia Química e Biológica, Oeiras 2785-572, Portugal.

Keywords: Frataxin, Friedreich’s ataxia (FRDA), progressive ataxia, cardiomyopathy, Fe-S assembly, Isu, functional regions, α1/β1 acidic ridge, β-sheet surface, iron binding region.

Full text pdf

Human ISCA1 Interacts with IOP1/NARFL and Functions in Both Cytosolic and Mitochondrial Iron-Sulfur Protein Biogenesis

Daisheng Song, Zheng Tu, Frank S. Lee.
From the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Keywords: Iron-sulfur proteins,  IscA,  isc (iron-sulfur cluster) operon,  IscA1,  succinate dehydrogenase,  mitochondrial aconitase, cytosolic aconitase, IOP1 (iron-only hydrogenase-like protein 1)/NARFL (nuclear prelamin A recognition factor-like).

Sunday, December 13, 2009

Clinical measures of dysarthria in Friedreich Ataxia

Movement Disorders, Early View (Articles online in advance of print),Published Online: 11 Dec 2009

Arunjot Singh, MS, Elizabeth Epstein, BA, Lauren M. Myers, BA, Jennifer M. Farmer, MS, David R. Lynch, MD, PhD
 Departments of Neurology and Pediatrics, University of Pennsylvania School of Medicine and The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Keywords: ataxia, sensory neuron, dysarthria, balance, clinical trial, Friedreich Ataxia (FA), speech, therapeutic monitoring.

AF4 Is a Critical Regulator of the IGF-1 Signaling Pathway during Purkinje Cell Development

The Journal of Neuroscience, December 9, 2009, 29(49):15366-15374; doi:10.1523/JNEUROSCI.5188-09.2009

Emmanuelle Bitoun,1,2 * Mattéa J. Finelli,1,2 * Peter L. Oliver,1,2 Sheena Lee,1 and Kay E. Davies1,2
1Medical Research Council Functional Genomics Unit, and 2Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3QX, United Kingdom

 Keywords:  insulin-like growth factor 1 (IGF-1), cerebellar ataxia,  neuronal cell death, targeted for therapy,  Purkinje cell (PC) death, cerebellum, transcriptional cofactor.

Friday, December 11, 2009

Novel Synchrotron-Based Analyses of Metal Pathology in Friedreich’s Ataxia

University of Saskatchewan Library,  Electronic Theses & Dissertations
Document Type Thesis

Popescu, Bogdan Florin GH.

Keywords: Copper, Iron, Zinc, Rapid Scanning X-ray Fluorescence Mapping, Synchrotron, Brain, Metals, Neurodegeneration, Friedreich's ataxia.

Full text pdf

Thursday, December 10, 2009

The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia.

J Mol Med. 2009 Dec 9.

Richardson DR, Huang ML, Whitnall M, Becker EM, Ponka P, Suryo Rahmanto Y.


Iron Metabolism and Chelation Program, Department of Pathology and Bosch Institute, Blackburn Building (D06), University of Sydney, Sydney, NSW, 2006, Australia, d.richardson@med.usyd.edu.au.

Keywords: Friedreich's ataxia, cardio- and neurodegenerative disease, frataxin, mitochondrial iron-overload, transferrin receptor-1 upregulation, ferritin, ferroportin1, mitoferrin2, iron-sulfur cluster (ISC), mitochondrial ferritin, compensatory alterations.

Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients

Gene Expression Omnibus, Series GSE11204
Experiment type Expression profiling by array, Public on Dec 08, 2009

Keywords: Friedreich's ataxia; frataxin; mitochondrial DNA damage; nuclear DNA damage; genotoxic stress

Wednesday, December 9, 2009

A Wireless Brain-Machine Interface for Real-Time Speech Synthesis

"Perhaps the most debilitating aspect of profound paralysis due to accident, stroke, or disease is loss of the ability to speak. The loss of speech not only makes the communication of needs to caregivers very difficult, but it also leads to profound social isolation of the affected individual."


PLoS ONE 4(12): e8218. doi:10.1371/journal.pone.0008218

OPEN ACCESS

Frank H. Guenther1,2*, Jonathan S. Brumberg1,3, E. Joseph Wright3, Alfonso Nieto-Castanon4, Jason A. Tourville1, Mikhail Panko1, Robert Law1, Steven A. Siebert3, Jess L. Bartels3, Dinal S. Andreasen3,5, Princewill Ehirim6, Hui Mao7, Philip R. Kennedy3

1 Department of Cognitive and Neural Systems and Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, Massachusetts, United States of America, 2 Division of Health Sciences and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America, 3 Neural Signals Inc., Duluth, Georgia, United States of America, 4 StatsANC LLC, Buenos Aires, Argentina, 5 Georgia Tech Research Institute, Marietta, Georgia, United States of America, 6 Gwinnett Medical Center, Lawrenceville, Georgia, United States of America, 7 Emory Center for Systems Imaging, Emory University Hospital, Atlanta, Georgia, United States of America

Abstract
Background: Brain-machine interfaces (BMIs) involving electrodes implanted into the human cerebral cortex have recently been developed in an attempt to restore function to profoundly paralyzed individuals. Current BMIs for restoring communication can provide important capabilities via a typing process, but unfortunately they are only capable of slow communication rates. In the current study we use a novel approach to speech restoration in which we decode continuous auditory parameters for a real-time speech synthesizer from neuronal activity in motor cortex during attempted speech.

Methodology/Principal Findings: Neural signals recorded by a Neurotrophic Electrode implanted in a speech-related region of the left precentral gyrus of a human volunteer suffering from locked-in syndrome, characterized by near-total paralysis with spared cognition, were transmitted wirelessly across the scalp and used to drive a speech synthesizer. A Kalman filter-based decoder translated the neural signals generated during attempted speech into continuous parameters for controlling a synthesizer that provided immediate (within 50 ms) auditory feedback of the decoded sound. Accuracy of the volunteer's vowel productions with the synthesizer improved quickly with practice, with a 25% improvement in average hit rate (from 45% to 70%) and 46% decrease in average endpoint error from the first to the last block of a three-vowel task.

Conclusions/Significance: Our results support the feasibility of neural prostheses that may have the potential to provide near-conversational synthetic speech output for individuals with severely impaired speech motor control. They also provide an initial glimpse into the functional properties of neurons in speech motor cortical areas.

Full text pdf

Supplementation with the reduced form of Coenzyme Q10 decelerates phenotypic characteristics of senescence and induces a peroxisome proliferator-activated receptor- gene expression signature in SAMP1 mice

Molecular Nutrition & Food Research
Received: 4 April 2009; Revised: 10 June 2009; Accepted: 30 June 2009.

Constance Schmelzer 1, Hiroshi Kubo 2, Masayuki Mori 3, Jinko Sawashita 3, Mitsuaki Kitano 2, Kazunori Hosoe 4, Inka Boomgaarden 1, Frank Döring 1 *, Keiichi Higuchi 3


1Institute of Human Nutrition and Food Science, Molecular Prevention, Christian-Albrechts-University of Kiel, Kiel, Germany
2Kaneka Corporation, Frontier Biochemical and Medical Research Laboratories, Takasago, Hyogo, Japan
3Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
4Kaneka Corporation, Functional Food Ingredients Division, Osaka, Japan

Keywords:  CoQ10, gene expression, inflammation, lipid metabolism, peroxisome proliferator-activated receptor- alpha, reduced form (Q10H2) coenzyme Q10 (CoQ10),  liver, heart, brain,  kidney,  stronger impact on gene expression, bioavailability, degenerative processes.

Monday, December 7, 2009

Friedreich Ataxia: An Update on Animal Models, Frataxin Function and Therapies

Advances in experimental medicine and biology,   ISSN 0065-2598  CODEN AEMBAP. 2009, vol. 652, pp. 247-261 [15 page(s) (article)

GONZALEZ-CABO Pilar ; VICENTE LLORENS José ; PALAU Francesc ; MOLTO Maria Dolores ;  

Keywords: Friedreich ataxia ; Frataxin ; Mitochondria ; Iron-sulfur clusters ; Oxidative stress ; Oxidative phosphorylation ; Antioxidant therapy ; Iron chelators ; Recombinant human erythropoietin ; Histone deacetylase inhibitors ;

Sunday, December 6, 2009

PGC-1 activation as a therapeutic approach in mitochondrial disease

IUBMB IUBMB Life, 61(11): 1051-1062, 2009

Tina Wenz.
Department of Neurology, University of Miami School of Medicine, Miami, FL 33136, USA

Keywords: Mitochondria,  cellular homeostasis, mitochondrial dysfunction, ATP,  OXPHOS, PGC-1.

Friday, December 4, 2009

Impairment in motor reprogramming in Friedreich ataxia reflecting possible cerebellar dysfunction.

J Neurol. 2009 Dec 3

Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children's Hospital, 10th Floor, Flemington Road, Parkville, VIC, 3052, Australia.

Keywords: cerebellar and spinocerebellar dysfunction, Friedreich ataxia (FRDA), motor function, cortical pathology, cerebello-cortical projections, , mov6ement execution, movement preparation, age of onset.

Thursday, December 3, 2009

Oxidative Stress Studies in Yeast With a Frataxin Mutant; A Proteomics Perspective

Proteome Res., Just Accepted Manuscript
Publication Date (Web): December 3, 2009
 
Jin-Hee Kim , Miroslav Sedlak , Qiang Gao , Catherine P Riley , Fred Regnier and Jiri Adamec
 
Department of Chemistry, Laboratory of Renewable Resources Engineering, Department of Agricultural and Biological Engineering, Bindley Bioscience Center at Discovery Park, Purdue University, West Lafayette, IN USA 47907

Keywords: Cellular response, Δyfh1 mutant, oxidative stress, iron, mitochondria,  carbonyl groups, reactive oxygen species (ROS), proteomic techniques, protein carbonylation.
 

Absence of aprataxin gene mutations in a Greek cohort with sporadic early onset ataxia and normal GAA triplets in frataxin gene.

Neurol Sci. 2009 Dec 2.

Laboratory of Neurogenetics, Neuroscience Unit, Department of Neurology, Faculty of Medicine, University of Thessalia, Larissa, Greece.

Keywords: Phenotype, aprataxin gene mutation,  GAA expansion,  frataxin gene, exons, flanking intronic sequences, cerebellar ataxia, point mutation, Friedreich ataxia.

A neurite quality index and machine vision software for improved quantification of neurodegeneration

BioTechniques, Vol. 47, No. 6, December 2009, pp. iii–viii

Peggy L. Romero1, Ted Miller2, and Arman M. Garakani2
1Sirtris, A GSK Company, Cambridge, MA, USA
2Reify Corporation, Saratoga, CA, USA
 
Keywords: neurodegradation in dorsal root ganglion cultures,  model for neurodegenerative diseases, quantify neuroprotection, neurite quality index (NQI),  neurosight,  vision-based method, SIRT1, resveratrol, nicotinamide adenine dinucleotide (NAD), axons.
 
Full text pdf

Wednesday, December 2, 2009

Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer

Curr Genomics. 2009 June; 10(4): 281–293. doi: 10.2174/138920209788488517.

E Kirches*

Department of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany

OPEN ACCESS

.../...
3. OTHER NUCLEAR-ENCODED MITOCHONDRIAL PROTEINS DISCUSSED IN CANCER
3.1. Does Frataxin Play an Inhibiting Role in ROS-Mediated Tumorigenesis ?
Friedreich’s ataxia is a severe neurodegenerative disease of adulthood, often accompanied by cardial hypertrophy and usually leading to the patient’s death within 15 years. It is inherited as a recessive autosomal trait, caused by an intronic GAA trinucleotid expansion in the frataxin gene, which switches off transcription of the affected allele [55]. Frataxin is a mitochondrial protein, which is suggested to be involved in iron homeostasis in the mitochondria, since a reduced amount of the protein in patients with the intragenic trinucleotide expansion leads to intramitochondrial iron deposits. Although the details of frataxin function are currently a matter of debate, these deposits may indicate an insufficient transport of iron to the sites of iron-sulfur cluster biogenesis by frataxin [56-59], which in turn may hamper the incorporation of correctly iron-loaded Fe/S-clusters into various mitochondrial proteins, such as the Fe/S-containing ETC complexes. In cell cultures, frataxin inactivation was shown to result in ETC inhibition, as demonstrated by a diminished mitochondrial membrane potential, decreased O2-consumption and decreased oxidative ATP synthesis. Frataxin dysfunction may lead to an inhibition of mitochondrial energy metabolism. On the other hand, a dysfunction of ETC complexes, as well as deposits of free iron (by Fenton reaction) can cause enhanced generation of ROS in the mitochondrial matrix and in the intermembrane space. Oxidative stress is thought to further damage ETC complexes and other redox-sensitive proteins, such as the Krebs cycle enzyme aconitase. This oxidative stress component may further inhibit intermediary metabolism and oxidative ATP synthesis.

Ristow and colleagues analyzed for the first time a potential tumor suppressing function of frataxin in cell culture and animal models, although patients suffering from Friedreich’s ataxia are in no way prone to a higher tumor burden. The idea behind this work was a potential connection between the antioxidative properties of frataxin and ROS-mediated tumorigenesis. The authors analyzed this topic initially in murine 3T3L1 cells, which had been transfected with either a vector expressing human frataxin or a control construct [60]. Both cell clones were exposed to culture conditions with artificially enhanced ROS production. The cells overexpressing frataxin exhibited a significantly lower number of anchorage-independent foci in the culture dishes and the rate of colony formation in soft agar assays was significantly lower, indicating that frataxin protected the cells from ROS-induced transformation into a tumor phenotype. This was further supported by the observation that only cells from the anchorage-independent foci were able to induce tumor growth when xenografted to nude mice.

While oxidative stress in frataxin-deficient patients with Friedreich’s ataxia may be due to the disturbed synthesis of Fe/S-clusters and mitochondrial iron deposits, it is less obvious as to how enforced overexpression of frataxin in normal cells may protect them against ROS. The authors explained the protective effect by the observed increase in glutathione peroxidase (GPx) activity and in reduced thiols. GPx and the reduced form of glutathione play an important role in the detoxification of H2O2, which is built as a product of the SOD- (superoxide dismutase) reaction. Superoxide dismutase 2 (SOD2) is a mitochondrial enzyme, which detoxifies superoxide radicals, released mainly from ETC complexes I and III into the mitochondrial matrix.

In a next step, the authors investigated the potential tumor suppressing effect of enforced frataxin expression in the colon cancer lines MIP101, DLD2 and HT29, which lack endogenous expression of the protein. Mitochondrial oxidative metabolism was enhanced in the transfected cells, as could be shown by an increase of mitochondrial membrane potential, cellular respiration and ATP content, as well as aconitase activity. Increased aconitase activity may be explained in part by decreased oxidative stress. Again, the frataxin cells exhibited a lower colony formation rate in soft agar essays and a lower rate of tumor growth after xenotransplantation to nude mice [61]. The most direct evidence for a role of frataxin in carcinogenesis was reported by the same group using targeted hepatic disruption of frataxin expression in mice. The animals had reduced life spans and developed multiple hepatic tumors, in which high apoptotic and mitotic (Ki-67) indices were observed [62]. The liver specimen showed elevated levels of thiobarbituric-acid reactive substances (TBARS), a marker of lipid peroxidation, and elevated levels of oxidized glutathione, a classical oxidative stress marker. Activities of those mitochondrial enzymes, which contain Fe/S-moieties, i.e. aconitase and ETC complexes I, II, III, were reduced. In accordance with an inhibited oxidative metabolism, the ATP content of livers from knock-out animals was decreased.

The authors did not develop a detailed hypothesis regarding the mechanism of liver tumorigenesis, but speculated that an observed reduction in p38-MAP-kinase phosphorylation may play a role, since activation of this type of mitogen activated protein kinase had been discussed earlier as a factor suppressing the formation of hepatic tumors [63, 64]. Although the authors did not discuss this issue, it might be speculated, whether the observed inhibition of SDH (complex II) may participate in tumorigenesis.
 
.../...

Coenzyme Q10 and Neurological Diseases

Pharmaceuticals 2009, 2, 134-149; doi:10.3390/ph203134

OPEN ACCESS


Michelangelo Mancuso *, Daniele Orsucci, Valeria Calsolaro, Anna Choub and Gabriele Siciliano
Department of Neuroscience, Neurological Clinic, University of Pisa, Tuscany, Italy

Abstract: Coenzyme Q10 (CoQ10, or ubiquinone) is a small electron carrier of the mitochondrial respiratory chain with antioxidant properties. CoQ10 supplementation has been widely used for mitochondrial disorders. The rationale for using CoQ10 is very powerful when this compound is primary decreased because of defective synthesis. Primary CoQ10 deficiency is a treatable condition, so heightened “clinical awareness” about this diagnosis is essential. CoQ10 and its analogue, idebenone, have also been widely used in the treatment of other neurodegenerative disorders. These compounds could potentially play a therapeutic role in Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, Friedreich’s ataxia, and other conditions which have been linked to mitochondrial dysfunction. This article reviews the physiological roles of CoQ10, as well as the rationale and the role in clinical practice of CoQ10 supplementation in different neurological diseases, from primary CoQ10 deficiency to neurodegenerative disorders.
Keywords: coenzyme Q10;  idebenone;  mitochondria; mitochondrial diseases; neurodegeneration

Tuesday, December 1, 2009

Can rehabilitation help ataxia?

Neurology, Vol. 73, Issue 22, 1818-1819, December 1, 2009 , EDITORIALS
Susanne M. Morton and Amy J. Bastian

Intensive coordinative training improves motor performance in degenerative cerebellar disease

NEUROLOGY 2009;73:1823-1830

W. Ilg, PhD, M. Synofzik, MD, D. Brötz, S. Burkard, M. A. Giese, PhD and L. Schöls, MD


From the Departments of Cognitive Neurology (W.I., M.A.G.) and Neurodegeneration (M.S., L.S.), Hertie Institute for Clinical Brain Research and Center of Neurology, Tübingen; Institute of Medical Psychology and Behavioral Neurobiology (D.B.), MEG Center, University Tübingen; and Therapy Centre (S.B.), Center of Neurology, University Clinic Tübingen, Germany.

Keywords: cerebellum, motor control, motor learning, physiotherapeutic training, cerebellar degeneration,  clinical ataxia rating scales, individual goal attainment scores, quantitative movement analysis, gait like velocity, lateral sway, intralimb coordination, standard of care, Berg balance score, goal attainment score, ICARS, international cooperative ataxia rating scale, SARA, scale for the assessment and rating of ataxia.